Strategic Global Advisors LLC Takes Position in Becton, Dickinson and Company $BDX

Strategic Global Advisors LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 30,530 shares of the medical instruments supplier’s stock, valued at approximately $4,620,000.

Several other large investors also recently modified their holdings of BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. raised its holdings in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc bought a new position in Becton, Dickinson and Company in the second quarter valued at approximately $29,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BDX has been the subject of several research reports. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Bank of America dropped their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $185.67.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,704 shares of company stock valued at $1,963,618 in the last quarter. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 0.2%

Becton, Dickinson and Company stock opened at $190.22 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company’s 50-day moving average is $164.35 and its 200-day moving average is $160.49. The firm has a market capitalization of $52.41 billion, a PE ratio of 57.30, a P/E/G ratio of 13.38 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.